Other languages Genenta Science S.p.A.

Equities

GNTA

US36870W1009

Market Closed - Nasdaq Other stock markets 02:00:00 13/06/2024 am IST			5-day change	1st Jan Change
3.15 ^USD	-4.55%		-1.59%	-36.36%

06/05	Genenta Science S.p.A. Announces New Board Appointments	CI
08/04	Genenta Science S.P.A. Announces Resignation of Board Members	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Genenta Science S.p.A. Announces New Board Appointments	06/05
Genenta Science S.P.A. Announces Resignation of Board Members	09/04
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03
Genenta Science Demonstrated Reprogramming of the Tumor Microenvironment in Gbm Patients, Paving the Way for Innovative Treatments of Solid Tumors	08/02
Sandoz kauft Medikament Cimerli für 170 Millionen US-Dollar von Coherus	22/01
Genenta Science S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2023	21/23/21
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	28/23/28
Health Care Stocks Support American Depositary Receipts of European Equities	16/23/16
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2022	22/23/22
Genenta Science S.p.A. Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications	03/23/03
Genenta Science Says Temferon Receives US FDA's Orphan Drug Designation for Treatment of Glioblastoma Multiforme	02/23/02
FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme	02/23/02
Genenta Science Signs Development, Manufacturing Deal With AGC Biologics	07/23/07
Genenta Science S.P.A. and Ospedale San Raffaele S.R.L. Enters into License Agreement	23/22/23
Genenta Science S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2022	25/22/25
Genenta Science S.p.A Shares Plunge After HC Wainwright Initiates Coverage	25/22/25
European ADRs Move Higher in Tuesday Trading	17/22/17
European ADRs Decline in Wednesday Trading	04/22/04
Genenta Science S.P.A. Announces Ongoing Trial of Temferon™	04/22/04
Genenta Science Announces Preliminary Findings from its Phase 1/2A of Temferon™ in the Treatment of Patients with Glioblastoma	03/22/03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Genenta Science S.p.A.

Equities

GNTA

US36870W1009

Other languages

Filters